[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614126":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":28,"responsibleParty":46,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University Hospital, Martin","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"kidney transplant recipients - Protocol Biopsy Cohort",null,"Adult kidney transplant recipients undergoing routine protocol biopsies at 3 and 12 months post-transplant, regardless of clinical graft function. Platelet aggregation, flow-cytometric P-selectin expression, soluble P-selectin levels, and biochemical and immunological parameters are collected at each time point.\n\nFindings from platelet function testing are subsequently correlated with the histopathological results of the protocol biopsy, including the presence or absence of subclinical rejection.",{"label":13,"type":10,"description":14,"interventionNames":10},"kidney transplant recipients - Indication Biopsy Cohort","Kidney transplant recipients presenting with clinical signs of graft dysfunction-such as rising serum creatinine, increasing proteinuria, or abnormal ultrasound findings or with newly positive donor-specific antibodies (DSA) detected by Luminex testing, prompting the need for an indication biopsy due to suspected acute rejection. At the time of biopsy, platelet aggregation testing, P-selectin markers, comprehensive biochemical parameters, and DSA levels are collected. This cohort represents patients with clinically or immunologically apparent graft injury, allowing comparison with protocol-biopsied patients, including those with subclinical or biopsy-confirmed rejection.",[16],{"name":17,"affiliation":18,"role":19},"Matej Vnucak, ass prof, MD, PhD.","University Hospital Martin and Jessenius Faculty of Medicine, Comenius University","STUDY_CHAIR",[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Timea Blichova, MD","CONTACT","+421434203184","tc@unm.sk",{"name":27,"role":23,"phone":24,"phoneExt":10,"email":25},"Patricia Kleinova, MD",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Transplant-Nephrology Department, University Hospital Martin","RECRUITING","Martin","03601","Slovakia","SK",{"type":37,"coordinates":38},"Point",[39,40],18.92399,49.06651,{"lat":40,"lon":39},[43,44],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":45,"role":23,"phone":24,"phoneExt":10,"email":25},"Matej Vnucak, ass prof., MD, PhD.",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Matej Vnucak","ass. prof., Deputy Head of Transplant-Nephrology Department","100614126","platelet-aggregation-in-the-diagnosis-of-acute-graft-rejection-100614126",false,"NCT07275541","Platelet Aggregation in the Diagnosis of Acute Graft Rejection","Inclusion Criteria:\n\n* adult patients (≥18 years)\n* primary kidney transplantation\n* living \u002F deceased donor kidney transplantation\n* ability and consent to participate\n\nExclusion Criteria:\n\n* non-adult patients\n* secondary \u002F tertiary kidney transplantation\n* antiplatelet therapy\n* patients unable to provide informed consent","ALL","18 Years",{"count":59,"type":60},60,"ESTIMATED","OBSERVATIONAL","The study titled \"Platelet Aggregation in the Diagnosis of Acute Graft Rejection\" is a pilot observational study evaluating whether alterations in platelet function can serve as non-invasive markers of acute rejection in kidney transplant recipients. Platelet aggregation is assessed using optical aggregometry, flow-cytometric P-selectin (CD62-P) expression, and soluble P-selectin levels before kidney transplantation and at the time of protocol biopsies performed at 3 and 12 months after kidney transplantation. Patients with suspected graft dysfunction undergoing indication biopsy are also included. Platelet activation markers are correlated with histopathological findings, donor-specific antibodies, metabolic parameters, and clinical outcomes. The goal is to determine whether platelet activation profiles can identify acute cellular or antibody-mediated rejection and contribute to the development of a non-invasive diagnostic tool.",[64,65],"Platelet Aggregation","Kidney Transplant Rejection",[67,68,69,70],"kidney transplantation","platelet aggregation","acute rejection","non-invasive marker","2025-11-27",{"date":73,"type":74},"2025-12-10","ACTUAL",{"date":76,"type":74},"2024-11-26",{"date":78,"type":60},"2027-11-26",{"name":5,"class":6},1]